Madrigal Pharmaceuticals, Inc. MDGL Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -31.3%+245pp | -276.4%— | —— | —— | |
| Net margin | -30.1%+229pp | -258.6%— | —— | —— | |
| EBITDA margin | -31.2%+245pp | -275.8%— | —— | —— | |
| Returns | |||||
| Return on equity | -42.5%+37.9pp | -80.3%+43.6pp | -124%+26.1pp | -150.1%-39.2pp | |
| Return on assets | -25%+30.3pp | -55.4%+19.1pp | -74.5%+18.4pp | -92.9%-6.6pp | |
| Return on invested capital | -39.6%+44.0pp | -83.6%— | —— | —— | |
| Efficiency | |||||
| Asset turnover | 0.8×+0.6× | 0.2×— | 0×— | 0×— | |
| Liquidity | |||||
| Current ratio | 4×-2.1× | 6.1×+0.7× | 5.4×+2.3× | 3.1×-0.4× | |
| Quick ratio | 3.8×-2.1× | 5.9×+0.5× | 5.4×+2.3× | 3.1×-0.4× | |
| Cash ratio | 0.7×0.0× | 0.6×-0.2× | 0.8×-2.0× | 2.9×+2.4× | |
| Leverage | |||||
| Debt-to-equity | 0.6×+0.4× | 0.2×-0.1× | 0.3×0.0× | 0.3×+0.2× | |
| Debt-to-assets | 0.3×+0.2× | 0.1×-0.1× | 0.2×0.0× | 0.1×+0.1× | |
| Interest coverage | -13.5×+20.5× | -33.9×-4.0× | -29.9×+44.1× | -74.1×— | |
| Per Share | |||||
| Book value per share | $21.21-24.3% | $28.04+36.7% | $20.51+79.1% | $11.45-0.3% | |
| Valuation | |||||
| Market capitalization | $13.23B+96.5% | $6.73B+47.3% | $4.57B-11.8% | $5.18B+257% | |
| Enterprise value | $13.37B+98.2% | $6.74B+47.1% | $4.59B-6.4% | $4.9B+246% | |
| Price / sales | 13.8×-23.6× | 37.4×— | —— | —— | |
| Price / book | 21.9×+13.0× | 8.9×-2.3× | 11.3×-15.0× | 26.2×+18.8× | |
| EV / sales | 13.9×-23.5× | 37.4×— | —— | —— | |
| Earnings yield | -2.2%+4.7pp | -6.9%+1.3pp | -8.2%-2.5pp | -5.7%+11.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Madrigal Pharmaceuticals, Inc.'s profit margins?
- Madrigal Pharmaceuticals, Inc. (MDGL) runs a 96.5% gross margin and a -27.7% operating margin, with a -27.3% net margin.
- Where do Madrigal Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Madrigal Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
